Prognostic value of morphologic and clinical parameters in pT2 - pT3 prostate cancer
| Autor: | Selma A S Kuckelhaus, Anamélia Lorenzetti Bocca, Jose C. Almeida, Raissa P. Menezes, Florêncio Figueiredo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Male
Pathology medicine.medical_specialty Prostatectomia Prognóstico Urology medicine.medical_treatment Disease urologic and male genital diseases lcsh:RC870-923 Statistics Nonparametric prostatic neoplasms chemistry.chemical_compound Prostate cancer Molecular marker Biopsy Biomarkers Tumor medicine Humans biopsy Stage (cooking) Pathological Aged Neoplasm Staging medicine.diagnostic_test prostatectomy business.industry Prostatectomy Middle Aged medicine.disease lcsh:Diseases of the genitourinary system. Urology Próstata - câncer chemistry Próstata - doenças immunohistochemistry Immunohistochemistry pathology prognosis business |
| Zdroj: | International Brazilian Journal of Urology, Vol 33, Iss 5, Pp 662-672 (2007) International braz j urol, Volume: 33, Issue: 5, Pages: 662-672, Published: OCT 2007 International braz j urol v.33 n.5 2007 International Braz J Urol Sociedade Brasileira de Urologia (SBU) instacron:SBU Repositório Institucional da UnB Universidade de Brasília (UnB) instacron:UNB Repositório Institucional da UCB Universidade Católica de Brasília (UCB) instacron:UCB |
| ISSN: | 1677-6119 1677-5538 |
| Popis: | Made available in DSpace on 2016-10-10T03:51:31Z (GMT). No. of bitstreams: 5 Prognostic Value ofMorphologic and clinical Parameters in pT2_pT3 Prostate Cancer.pdf: 154965 bytes, checksum: 89887e2cc635c9cc9759a465c29c3728 (MD5) license_url: 52 bytes, checksum: 3d480ae6c91e310daba2020f8787d6f9 (MD5) license_text: 21716 bytes, checksum: c200d7a52028dd255d79d7c917cc149a (MD5) license_rdf: 23005 bytes, checksum: 845fd6e03839c7264c0c164178b2e173 (MD5) license.txt: 1818 bytes, checksum: 46de3043f08e87659ae535ef74b8ce9d (MD5) Previous issue date: 2007 Objectives:Verify the efficacy of clinical and morphologic parameters currently applied, including an immunohistochemical panel, in the prognostic of prostate cancer, in specific stages of the disease. Materials and Methods: In the period from 2002 to 2005, 40 surgical specimens were selected from patients submitted to radical prostatectomy, with their respective diagnostic biopsies. Based on the pathological stage pT2 or pT3, the specimens were separated into two groups, each one with 20 specimens. The results were confronted with pre- and postoperative clinical data. Between the groups studied, the following was also analyzed: the profile of the expression of molecular markers such as PSA, E-caderin, chromogranin-A, synaptofisin, P53 and Ki-67, both in the material coming from the prostatic biopsy and from the surgical specimens of all patients. Results: Data showed that patients with prostate-confined disease (pT2) presented lower PSA and Gleason score rates, in relation to the group with extra-prostatic disease (pT3). Quantitative measures obtained for the percentage of positive fragments from the biopsy revealed that patients from the pT2 group presented a lower mean percentage when compared to the pT3 group. Positive margins of both groups influenced the need for complementary treatment before biochemical progression. The comparison of the molecular marker expression in both stages was not significantly different. Conclusion: It is evident the need to improve new methods, predominantly morphologic and molecular, that are able to further exploit the study of the material from the prostatic biopsy. As to the profile of the molecular markers used in both studied groups, there was no significant difference in the sense of outlining an additional prognostic factor in the clinical practice. Publicado |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|